<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d50" origId="Capecitabine"><sentence id="DrugDDI.d50.s0" origId="s0" text="Antacid The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients."><entity id="DrugDDI.d50.s0.e0" origId="s0.p1" charOffset="25-44" type="drug" text="aluminum hydroxide"/><entity id="DrugDDI.d50.s0.e1" origId="s0.p3" charOffset="49-88" type="drug" text="magnesium hydroxide-containing antacid"/><entity id="DrugDDI.d50.s0.e2" origId="s0.p5" charOffset="89-95" type="drug" text="Maalox"/><entity id="DrugDDI.d50.s0.e3" origId="s0.p9" charOffset="125-137" type="drug" text="capecitabine"/><pair id="DrugDDI.d50.s0.p0" e1="DrugDDI.d50.s0.e0" e2="DrugDDI.d50.s0.e1" interaction="false"/><pair id="DrugDDI.d50.s0.p1" e1="DrugDDI.d50.s0.e0" e2="DrugDDI.d50.s0.e2" interaction="false"/><pair id="DrugDDI.d50.s0.p2" e1="DrugDDI.d50.s0.e0" e2="DrugDDI.d50.s0.e3" interaction="false"/><pair id="DrugDDI.d50.s0.p3" e1="DrugDDI.d50.s0.e1" e2="DrugDDI.d50.s0.e2" interaction="false"/><pair id="DrugDDI.d50.s0.p4" e1="DrugDDI.d50.s0.e1" e2="DrugDDI.d50.s0.e3" interaction="false"/><pair id="DrugDDI.d50.s0.p5" e1="DrugDDI.d50.s0.e2" e2="DrugDDI.d50.s0.e3" interaction="false"/></sentence><sentence id="DrugDDI.d50.s1" origId="s1" text="There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);"><entity id="DrugDDI.d50.s1.e0" origId="s1.p17" charOffset="55-67" type="drug" text="capecitabine"/><entity id="DrugDDI.d50.s1.e1" origId="s1.p19" charOffset="76-86" type="drug" text="metabolite"/><pair id="DrugDDI.d50.s1.p0" e1="DrugDDI.d50.s1.e0" e2="DrugDDI.d50.s1.e1" interaction="false"/></sentence><sentence id="DrugDDI.d50.s2" origId="s2" text="there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL)."><entity id="DrugDDI.d50.s2.e0" origId="s2.p27" charOffset="35-46" type="drug" text="metabolites"/><entity id="DrugDDI.d50.s2.e1" origId="s2.p30" charOffset="56-60" type="drug" text="5-FU"/><entity id="DrugDDI.d50.s2.e2" origId="s2.p32" charOffset="65-69" type="drug" text="FBAL"/><pair id="DrugDDI.d50.s2.p0" e1="DrugDDI.d50.s2.e0" e2="DrugDDI.d50.s2.e1" interaction="false"/><pair id="DrugDDI.d50.s2.p1" e1="DrugDDI.d50.s2.e0" e2="DrugDDI.d50.s2.e2" interaction="false"/><pair id="DrugDDI.d50.s2.p2" e1="DrugDDI.d50.s2.e1" e2="DrugDDI.d50.s2.e2" interaction="false"/></sentence><sentence id="DrugDDI.d50.s3" origId="s3" text="Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon."><entity id="DrugDDI.d50.s3.e0" origId="s3.p34" charOffset="0-22" type="drug" text="Coumarin Anticoagulant"/><entity id="DrugDDI.d50.s3.e1" origId="s3.p44" charOffset="109-121" type="drug" text="capecitabine"/><entity id="DrugDDI.d50.s3.e2" origId="s3.p45" charOffset="141-175" type="drug" text="coumarin-derivative anticoagulants"/><entity id="DrugDDI.d50.s3.e3" origId="s3.p46" charOffset="184-192" type="drug" text="warfarin"/><entity id="DrugDDI.d50.s3.e4" origId="s3.p48" charOffset="197-210" type="drug" text="phenprocoumon"/><pair id="DrugDDI.d50.s3.p0" e1="DrugDDI.d50.s3.e0" e2="DrugDDI.d50.s3.e1" interaction="false"/><pair id="DrugDDI.d50.s3.p1" e1="DrugDDI.d50.s3.e0" e2="DrugDDI.d50.s3.e2" interaction="false"/><pair id="DrugDDI.d50.s3.p2" e1="DrugDDI.d50.s3.e0" e2="DrugDDI.d50.s3.e3" interaction="false"/><pair id="DrugDDI.d50.s3.p3" e1="DrugDDI.d50.s3.e0" e2="DrugDDI.d50.s3.e4" interaction="false"/><pair id="DrugDDI.d50.s3.p4" e1="DrugDDI.d50.s3.e1" e2="DrugDDI.d50.s3.e2" interaction="true"/><pair id="DrugDDI.d50.s3.p5" e1="DrugDDI.d50.s3.e1" e2="DrugDDI.d50.s3.e3" interaction="false"/><pair id="DrugDDI.d50.s3.p6" e1="DrugDDI.d50.s3.e1" e2="DrugDDI.d50.s3.e4" interaction="true"/><pair id="DrugDDI.d50.s3.p7" e1="DrugDDI.d50.s3.e2" e2="DrugDDI.d50.s3.e3" interaction="false"/><pair id="DrugDDI.d50.s3.p8" e1="DrugDDI.d50.s3.e2" e2="DrugDDI.d50.s3.e4" interaction="false"/><pair id="DrugDDI.d50.s3.p9" e1="DrugDDI.d50.s3.e3" e2="DrugDDI.d50.s3.e4" interaction="false"/></sentence><sentence id="DrugDDI.d50.s4" origId="s4" text="Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR)."><entity id="DrugDDI.d50.s4.e0" origId="s4.p51" charOffset="16-50" type="drug" text="coumarin-derivative anticoagulants"/><entity id="DrugDDI.d50.s4.e1" origId="s4.p52" charOffset="70-82" type="drug" text="capecitabine"/><pair id="DrugDDI.d50.s4.p0" e1="DrugDDI.d50.s4.e0" e2="DrugDDI.d50.s4.e1" interaction="true"/></sentence><sentence id="DrugDDI.d50.s5" origId="s5" text="Leucovorin The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin."><entity id="DrugDDI.d50.s5.e0" origId="s5.p64" charOffset="0-10" type="drug" text="Leucovorin"/><entity id="DrugDDI.d50.s5.e1" origId="s5.p65" charOffset="34-46" type="drug" text="fluorouracil"/><entity id="DrugDDI.d50.s5.e2" origId="s5.p73" charOffset="96-106" type="drug" text="leucovorin"/><pair id="DrugDDI.d50.s5.p0" e1="DrugDDI.d50.s5.e0" e2="DrugDDI.d50.s5.e1" interaction="false"/><pair id="DrugDDI.d50.s5.p1" e1="DrugDDI.d50.s5.e0" e2="DrugDDI.d50.s5.e2" interaction="false"/><pair id="DrugDDI.d50.s5.p2" e1="DrugDDI.d50.s5.e1" e2="DrugDDI.d50.s5.e2" interaction="true"/></sentence><sentence id="DrugDDI.d50.s6" origId="s6" text="Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil."><entity id="DrugDDI.d50.s6.e0" origId="s6.p84" charOffset="116-126" type="drug" text="leucovorin"/><entity id="DrugDDI.d50.s6.e1" origId="s6.p86" charOffset="131-143" type="drug" text="fluorouracil"/><pair id="DrugDDI.d50.s6.p0" e1="DrugDDI.d50.s6.e0" e2="DrugDDI.d50.s6.e1" interaction="true"/></sentence></document>